“…The EPR effect varies among human tumors and sometimes shows poor vascular permeability, making it less reliable for effective drug delivery. Furthermore, drug accumulation depends largely on factors like circulation time and random extravasation into the tumor tissue in these systems, rather than targeted intracellular delivery, which can lead to inconsistent therapeutic outcomes, reduced bioavailability, and unintended off-target effects. , Given these limitations, active targeting systems have emerged by incorporating tumor-specific ligands like antibodies, peptides, and small molecules that bind to overexpressed receptors on cancer cells, allowing for receptor-mediated endocytosis, thereby increasing cell-specific internalization and intracellular uptake, which not only provides greater control over drug delivery but also offers the potential for reduced side effects, representing an important advancement over EPR-based passive targeting.…”